- Home
- PHT vs CDXS Comparison
PHT vs CDXS Comparison
Compare PHT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- CDXS
- Stock Information
- Founded
- PHT 2002
- CDXS 2002
- Country
- PHT United States
- CDXS United States
- Employees
- PHT N/A
- CDXS N/A
- Industry
- PHT Investment Managers
- CDXS Major Chemicals
- Sector
- PHT Finance
- CDXS Industrials
- Exchange
- PHT Nasdaq
- CDXS Nasdaq
- Market Cap
- PHT 244.7M
- CDXS 254.3M
- IPO Year
- PHT N/A
- CDXS 2010
- Fundamental
- Price
- PHT $8.32
- CDXS $2.73
- Analyst Decision
- PHT
- CDXS Buy
- Analyst Count
- PHT 0
- CDXS 2
- Target Price
- PHT N/A
- CDXS $11.00
- AVG Volume (30 Days)
- PHT 85.5K
- CDXS 1.3M
- Earning Date
- PHT 01-01-0001
- CDXS 08-13-2025
- Dividend Yield
- PHT 8.76%
- CDXS N/A
- EPS Growth
- PHT N/A
- CDXS N/A
- EPS
- PHT 0.98
- CDXS N/A
- Revenue
- PHT N/A
- CDXS $57,164,000.00
- Revenue This Year
- PHT N/A
- CDXS $12.88
- Revenue Next Year
- PHT N/A
- CDXS $21.64
- P/E Ratio
- PHT $7.71
- CDXS N/A
- Revenue Growth
- PHT N/A
- CDXS N/A
- 52 Week Low
- PHT $6.41
- CDXS $1.90
- 52 Week High
- PHT $7.60
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- PHT 68.90
- CDXS 45.89
- Support Level
- PHT $8.28
- CDXS $2.61
- Resistance Level
- PHT $8.37
- CDXS $2.79
- Average True Range (ATR)
- PHT 0.04
- CDXS 0.22
- MACD
- PHT -0.00
- CDXS -0.03
- Stochastic Oscillator
- PHT 68.75
- CDXS 9.52
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.